ABIVAX Société Anonyme (NASDAQ:ABVX) Receives Consensus Recommendation of “Buy” from Analysts

Shares of ABIVAX Société Anonyme (NASDAQ:ABVXGet Free Report) have been assigned a consensus rating of “Buy” from the seven brokerages that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $38.67.

ABVX has been the subject of several research analyst reports. JMP Securities reissued a “market outperform” rating and issued a $33.00 price objective on shares of ABIVAX Société Anonyme in a research note on Friday, January 10th. Citizens Jmp raised ABIVAX Société Anonyme to a “strong-buy” rating in a research note on Wednesday, December 4th.

Get Our Latest Stock Analysis on ABIVAX Société Anonyme

ABIVAX Société Anonyme Stock Up 0.2 %

Shares of NASDAQ ABVX opened at $6.10 on Thursday. The business has a fifty day simple moving average of $7.51 and a 200-day simple moving average of $9.88. ABIVAX Société Anonyme has a 12 month low of $5.54 and a 12 month high of $17.02.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Point72 Asset Management L.P. increased its holdings in shares of ABIVAX Société Anonyme by 28.2% during the 3rd quarter. Point72 Asset Management L.P. now owns 542,900 shares of the company’s stock valued at $6,254,000 after acquiring an additional 119,300 shares during the last quarter. abrdn plc increased its holdings in shares of ABIVAX Société Anonyme by 34.1% during the 4th quarter. abrdn plc now owns 424,181 shares of the company’s stock valued at $3,105,000 after acquiring an additional 107,750 shares during the last quarter. Walleye Capital LLC increased its holdings in shares of ABIVAX Société Anonyme by 45.8% during the 3rd quarter. Walleye Capital LLC now owns 257,417 shares of the company’s stock valued at $2,965,000 after acquiring an additional 80,807 shares during the last quarter. BNP Paribas Financial Markets increased its holdings in shares of ABIVAX Société Anonyme by 82.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 13,044 shares of the company’s stock valued at $150,000 after acquiring an additional 5,900 shares during the last quarter. Finally, R Squared Ltd acquired a new position in shares of ABIVAX Société Anonyme during the 4th quarter valued at about $36,000. 47.91% of the stock is owned by institutional investors and hedge funds.

ABIVAX Société Anonyme Company Profile

(Get Free Report

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.

Recommended Stories

Analyst Recommendations for ABIVAX Société Anonyme (NASDAQ:ABVX)

Receive News & Ratings for ABIVAX Société Anonyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIVAX Société Anonyme and related companies with MarketBeat.com's FREE daily email newsletter.